Bristol-Myers Squibb Company (ETR: BRM)
Germany
· Delayed Price · Currency is EUR
55.60
+0.85 (1.55%)
Dec 27, 2024, 5:35 PM CET
ETR: BRM Employees
Bristol-Myers Squibb Company had 34,100 employees as of December 31, 2023. The number of employees decreased by 200 or -0.58% compared to the previous year.
Employees
34,100
Change (1Y)
-200
Growth (1Y)
-0.58%
Revenue / Employee
€1,247,221
Profits / Employee
€190,836
Market Cap
112.18B
Employees Chart
Employees History
Bristol-Myers Squibb Company News
- 23 hours ago - Bristol Myers Squibb's (BMY) Opdivo Qvantig Approved for NSCLC Treatment - GuruFocus
- 1 day ago - U.S. Food and Drug Administration Approves Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo (nivolumab) Indications1,2 - Wallstreet:Online
- 1 day ago - U.S. Food and Drug Administration Approves Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo® (nivolumab) Indications1,2 - Benzinga
- 1 day ago - FDA Approval of Injectable Opdivo: Bristol Myers Squibb Fights Off Patent Cliff Concerns - GuruFocus
- 5 days ago - Bristol-Myers gets EU okay for Opdivo/Yervoy combo - Seeking Alpha
- 5 days ago - Bristol-Myers Squibb meets main goal in late-stage trials of its psoriatic arthritis treatment - Seeking Alpha
- 5 days ago - Bristol-Myers Squibb Co (BMY) Announces Positive Phase 3 Trial Results for Sotyktu in Psoriatic ... - GuruFocus
- 5 days ago - Bristol Myers Squibb Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis - Wallstreet:Online